T
The420Guy
Guest
Milan, Italy: Cannabidiol, a non-psychoactive compound in marijuana, is
protective against brain injury in animals, according to a study
published in this month's issue of Neuroscience Letters.
Researchers in Italy reported that administration of CBD in gerbils
prevented brain damage caused by ischemia (a reduction of blood flow to
the brain that can cause cell death).
"These findings suggest a potential therapeutic role of cannabidiol in
cerebral ischemia, though the clear mechanism of action remains to be
elucidated," authors concluded.
Federal law prohibits the medical use of any cannabinoid other than
synthetic THC.
A 1998 study published in the Proceedings of the National Academy of
Sciences (PNAS) found that CBD protected rat brain cells from injury
better than standard anti-oxidants.
A 1999 report by the National Academy of Sciences' Institute of Medicine
(IOM) concluded that marijuana's neuroprotective qualities are the "most
prominent" of its potential therapeutic applications.
Last week, the Israeli pharmaceutical company Pharmos announced the
commencement of the first ever Phase III US study on the effectiveness of
the synthetic marijuana derivative Dexanabinol to treat brain damage
resulting from Traumatic Brain Injury (TBI) and/or stroke.
Full text of the study appears in the July 31, 2003 issue of Neuroscience
Letters.
protective against brain injury in animals, according to a study
published in this month's issue of Neuroscience Letters.
Researchers in Italy reported that administration of CBD in gerbils
prevented brain damage caused by ischemia (a reduction of blood flow to
the brain that can cause cell death).
"These findings suggest a potential therapeutic role of cannabidiol in
cerebral ischemia, though the clear mechanism of action remains to be
elucidated," authors concluded.
Federal law prohibits the medical use of any cannabinoid other than
synthetic THC.
A 1998 study published in the Proceedings of the National Academy of
Sciences (PNAS) found that CBD protected rat brain cells from injury
better than standard anti-oxidants.
A 1999 report by the National Academy of Sciences' Institute of Medicine
(IOM) concluded that marijuana's neuroprotective qualities are the "most
prominent" of its potential therapeutic applications.
Last week, the Israeli pharmaceutical company Pharmos announced the
commencement of the first ever Phase III US study on the effectiveness of
the synthetic marijuana derivative Dexanabinol to treat brain damage
resulting from Traumatic Brain Injury (TBI) and/or stroke.
Full text of the study appears in the July 31, 2003 issue of Neuroscience
Letters.
